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  Ginsenosides are low molecular weight glycosides found in ginseng that exhibit neuroprotective effects 
through inhibition of N-methyl-D-aspartic acid (NMDA) receptor channel activity. Ginsenosides, like 
other natural compounds, are metabolized by gastric juices and intestinal microorganisms to produce 
ginsenoside metabolites. However, little is known about how ginsenoside metabolites regulate NMDA 
receptor channel activity. In the present study, we investigated the effects of ginsenoside metabolites, 
such as compound K (CK), protopanaxadiol (PPD), and protopanaxatriol (PPT), on oocytes that hetero-
logously express the rat NMDA receptor. NMDA receptor-mediated ion current (INMDA) was measured 
using the 2-electrode voltage clamp technique. In oocytes injected with cRNAs encoding NMDA receptor 
subunits, PPT, but not CK or PPD, reversibly inhibited INMDA in a concentration-dependent manner. 
The IC50 for PPT on INMDA was 48.1±4.6 μM, was non-competitive with NMDA, and was independent 
of the membrane holding potential. These results demonstrate the possibility that PPT interacts with 
the NMDA receptor, although not at the NMDA binding site, and that the inhibitory effects of PPT 
on  INMDA could be related to ginseng-mediated neuroprotection.
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INTRODUCTION
  Glutamate is a major excitatory neurotransmitter in the 
central nervous system (CNS) [1]. Glutamate not only inter-
acts with GTP-binding protein coupled receptors (i.e., me-
tabotropic glutamate receptor subtypes), but also binds to 
various ionotropic ligand-gated glutamate receptors, which 
include α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), kainite, and N-methyl-D-aspartic acid (NMDA) re-
ceptors [1,2]. NMDA receptors play a pivotal role in the 
regulation of synaptic function in the CNS [3]. In the hippo-
campus, NMDA receptors have important roles in physio-
logical functions such as learning and memory. In abnormal 
conditions, overstimulation of NMDA receptors causes ner-
vous system excitotoxicity [4,5], NMDA receptor inhibitors 
are currently under investigation for clinical applications.
  Ginseng, the root of Panax ginseng C.A. Meyer, has been 
used as a general tonic to promote longevity and enhance 
body functions to protect against stress, fatigue, diseases, 
cancer, and diabetes mellitus [6]. Recent studies have shown 
that, among the various ginseng components, ginsenosides 
(also called ginseng saponins) exhibit neuroprotective effects 
[7]. For example, we demonstrated that ginsenoside Rg3 at-
tenuated NMDA receptor-mediated ion currents as well as 
NMDA-mediated excitotoxicity in cultured neurons [8,9]. In 
addition, we also demonstrated that Rg3 inhibited voltage- 
gated Ca
2＋ and Na
＋ channel currents, which are also acti-
vated following NMDA receptor activation [10-13]. However, 
orally administered ginsenosides can be broken down by 
intestinal microorganisms [14]. Protopanaxadiol (PPD) gin-
senosides are metabolized by intestinal microorganisms in-
to compound K (CK), which has 1 glucose at the C-20 posi-
tion, and are further metabolized to form PPD, which has 
no glucose. In contrast, protopanaxatriol (PPT) ginseno-
sides are metabolized to PPT, which only has a ginsenoside 
backbone and no carbohydrate components (Fig. 1). A recent 
report showed that these ginsenoside metabolites might also 
induce apoptosis of cancer cells and function as an anti-can-
cer agent [15], suggesting that ginsenosides are the prodrugs 
of these metabolites. However, relatively little is known 
about how ginsenoside metabolites regulate receptor chan-114 TJ Shin, et al
Fig. 1. Chemical Structure of Ginse-
noside Rg3 and Ginsenoside Metabo-
lites and the Effects of Ginsenoside 
Metabolites on INMDA. (A) Chemical 
structure of ginsenoside Rg3 and 
ginsenoside metabolites. (B) Effect 
of ginsenoside metabolites on INMDA
in oocytes expressing the rat NMDA 
receptor. Application of NMDA (300
μM) and glycine (10 μM) elicited 
INMDA. Co-application of PPT (100 μ M) 
but not CK (100 μM) or PPD (100
μM) with NMDA (300 μM) and 
glycine (10 μM) attenuated INMDA. 
The traces represent 6 separate 
oocytes.
nel activity.
  The purpose of this study was to investigate how ginseno-
side metabolites affect NMDA receptor-mediated ion cur-
rent (INMDA). We report here that PPT inhibited INMDA,  while 
CK and PPD had no effect on INMDA.
METHODS
Materials
  The ginsenoside metabolites CK, PPD, and PPT were 
purchased from AMBO Institute (Seoul, Korea) (Fig. 1A). 
All other reagents were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).
Preparation of Xenopus laevis oocytes and microin-
jection
  X. laevis frogs were purchased from Xenopus I (Ann 
Arbor, MI, USA). Animal care and handling were carried 
out in accordance with the highest standards of the Konkuk 
University guidelines. To isolate oocytes, frogs were anes-
thetized with an aerated solution of 3-amino benzoic acid 
ethyl ester, and the ovarian follicles were removed. The oo-
cytes were separated by treatment with collagenase fol-
lowed by agitation for 2 h in Ca
2＋-free OR2 medium con-
taining 82.5 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM 
HEPES, 2.5 mM sodium pyruvate, 100 units/ml penicillin, 
and 100 μg/ml streptomycin. Stage V∼VI oocytes were col-
lected and stored in ND96 medium (96 mM NaCl, 2 mM 
KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM HEPES, pH 
7.5) supplemented with 50 μg/ml gentamicin. The oocyte- 
containing solution was maintained at 18
oC with continu-
ous gentle shaking and was replaced daily. Electrophysio-
logical experiments were performed 3 to 5 days after oocyte 
isolation. For the NMDA receptor experiments, NMDA re-
ceptor subunit-encoding cRNAs (40 nl) were injected into 
the animal or vegetal pole of each oocyte 1 day after iso-
lation using a 10-μl microdispenser (VWR Scientific, West 
Chester, PA, USA) fitted with a tapered glass pipette tip 
(15∼20 μm in diameter) [16].
Data recording
  A custom-made Plexiglas net chamber was used for 2- 
electrode voltage-clamp recordings, as previously reported 
[16]. A single oocyte was constantly superfused during re-
cording with a recording solution (96 mM NaCl, 2 mM KCl, 
0.3 mM CaCl2, and 5 mM HEPES, pH 7.6) in the presence 
or absence of NMDA or ginsenoside metabolites. The micro-
electrodes were filled with 3 M KCl and had a resistance 
of 0.2∼0.7 MΩ. Two-electrode voltage-clamp recordings 
were obtained at room temperature using an oocyte clamp 
(OC-725C; Warner Instrument, Hamden, CT, USA), and 
were digitized using Digidata 1200A (Molecular Devices, 
Sunnyvale, CA, USA). Stimulation and data acquisition 
were controlled using pClamp 8 software (Molecular Devi-
ces). For most electrophysiological data, the oocytes were 
clamped at a holding potential of －60 mV. To determine 
the current and voltage (I-V) relationship, voltage ramps 
were applied from －100 to ＋50 mV for 1 s. In the different 
membrane-holding potential experiments, the oocytes were 
clamped at the indicated holding potentials. Linear leak 
and capacitance currents were corrected by the leak sub-
traction procedure.
Data analysis 
  To obtain the concentration-response curve for the effect 
of PPT on the inward peak INMDA mediated by the NMDA 
receptor, the INMDA peak was plotted at different concen-
trations of PPT. Origin software version 8.0 (OriginLab 
Corp., Northampton, MA, USA) was used to fit the plot to 
the Hill equation: I/Imax=1/[1＋(IC50/[A])
nH], where Imax was 
maximal current obtained from the ED50 value of the 
NMDA receptor, IC50 was the concentration of PPT required 
to decrease the response by 50%, [A] was the concentration 
of PPT, and nH was the Hill coefficient. All values were 
presented as the mean±SEM. The differences between the 
of the control and treatment data were determined using 
the paired Student’s t-test. A p-value of less than 0.05 was 
considered statistically significant.Protopanaxatriol Inhibits NMDA Receptor-Mediated Ion Currents 115
Fig. 2. Concentration-dependent Effects of PPT Co-application with 
NMDA (300 μM) and Glycine (10 μM) on INMDA. PPT inhibited 
INMDA in a concentration-dependent manner. The traces represent 
6 separate oocytes.
Fig. 3. Current-voltage Relationship of PPT-mediated INMDA Inhibition
of the NMDA Receptor. Representative current-voltage relation-
ships were obtained using voltage ramps of －100 to ＋50 mV for 
1 s at a holding potential of －60 mV. Voltage steps were applied 
before and after application of 300 μM NMDA and 10 μM glycine 
in the presence or absence of 50 μM PPT. The reversal potential 
for the receptor was －14.70±0.9 mV and －13.82±0.9 mV in the 
presence and absence of PPT, respectively.
RESULTS
Effect of ginsenoside metabolites on INMDA in oocytes 
expressing the rat NMDA receptor
  In the present study, we examined the effect of the ginse-
noside metabolites CK, PPD, and PPT on NMDA receptor 
channel activity. We expressed the rat NMDA receptor 
NR1b and NR2B subunits in Xenopus  oocytes [17]. As 
shown in Fig. 1B, the addition of NMDA to the bathing 
solution induced a large inward current (INMDA) in oocytes 
injected with rat NMDA receptor subunit cRNAs. In H2O- 
injected control oocytes, the application of NMDA did not 
induce any inward currents (data not shown). CK, PPD, 
or PPT alone also had no effect in oocytes expressing the 
NMDA receptor at a holding potential of －60 mV (data 
not shown). However, co-application of PPT, but not CK or 
PPD, (at 100 μM) with NMDA (300 μM; with 10 μM gly-
cine, a co-agonist required for efficient opening of the ion 
channel [18]) for 40 s inhibited INMDA in oocytes expressing 
NMDA receptor in a reversible manner (Fig. 2, n=6∼9 from 
3 different frogs). In concentration-dependent experiments, 
co-application of PPT with NMDA for 40 s decreased INMDA 
in a concentration-dependent manner in oocytes expressing 
the NMDA receptor (Fig. 2). Therefore, co-application of 
PPT at 10, 30, 100, 300, and 1,000 μM decreased INMDA 
in oocytes expressing the NMDA receptor by 6.5± 11.0%, 
20.3±10.3%, 35.8±6.2%, 47.6±7.3%, and 50.8±8.9%, respec-
tively. The IC50 for PPT on INMDA was 48.1±4.6 μM (Fig. 
2, n= 10∼11, with samples taken from 3 different frogs for 
each point).
Current-voltage relationship and concentration-depen-
dent effects of NMDA on PPT-mediated inhibition of 
INMDA
  To examine the current-voltage relationship, the mem-
brane potential was held at －60 mV, and a voltage ramp 
was applied from －100 to ＋50 mV for 1 s. In the absence 
of NMDA, the inward current at －100 mV was less than 
0.2 μA, and the outward current at ＋50 mV was approx-
imately 0.2 μA (Fig. 3). The addition of NMDA to the gly-
cine containing bathing medium induced a mainly inward 
current at negative voltages and an outward current at posi-
tive voltages [19]. The reversal potentials were near －10 
mV for responses up to 300 μM NMDA (with 10 μM gly-
cine) both in the presence and absence of PPT (50 μM). 
Although co-application of PPT and NMDA decreased the 
currents, it did not affect the NMDA receptor channel prop-
erty because PPT did not change the reversal potential of 
the NMDA receptor (Fig. 3). To further examine the mecha-
nism by which co-application of PPT inhibits INMDA in oo-
cytes expressing the NMDA receptor, we analyzed the effect 
of PPT on INMDA evoked by different concentrations of 
NMDA (at a fixed glycine concentration of 10 μM) (Fig. 4A). 
Co-application of PPT (50 μM) for 40 s with different con-
centrations of NMDA significantly shifted the concen-
tration-response curve of NMDA to the right (EC50 values 
changed from 109.7±2.5 μM to 172.0±3.3 μM, p＜0.05). 
However, the Hill coefficient did not change significantly 
(1.27±0.27 to 1.22±0.17), indicating that the number of PPT 
molecules interacting with NMDA receptor did not change. 
Therefore, PPT- mediated inhibition of INMDA was not af-
fected by increasing concentrations of NMDA ranging from 
30 to 300 μM (Fig. 4A), suggesting that PPT-mediated in-
hibition of INMDA might be non-competitive. 
Effect of PPT on INMDA at different membrane holding 
potentials
 Since PPT-mediated inhibition of INMDA is not competitive 
with NMDA, we next examined whether PPT-mediated in-
hibition of INMDA is dependent on the membrane holding 
potential. 
  At different holding potentials, the INMDA elicited by 300 
μM NMDA (with 10 μM glycine) and 50 μM PPT was mea-
sured. Our results revealed that PPT-mediated inhibition 
of INMDA in oocytes expressing the rat NMDA receptor was 116 TJ Shin, et al
Fig. 4. Concentration-dependent Effects
of NMDA on PPT-mediated Inhibition
of  INMDA. (A) The representative 
traces shown for the indicated con-
centrations of NMDA represent 6 
separate oocytes from 3 different 
batches of frogs. (B) Concentration- 
response relationships for NMDA in 
NMDA receptors treated with NMDA
(10∼1000 μM; with 10 μM glycine) 
or with NMDA plus 50 μM PPT in 
oocytes expressing the rat NMDA 
receptor. The normalized INMDA of 
oocytes expressing the NMDA recep-
tor was measured at the indicated 
concentrations of NMDA in the pre-
sence (○) or absence (□) of 50 μM 
PPT. Oocytes were exposed to NMDA
alone or NMDA and PPT for 1 min 
prior to application. Oocytes were 
voltage-clamped at a holding poten-
tial of －60 mV. 
Fig. 5. Voltage-independent PPT- 
mediated  INMDA Inhibition of the 
NMDA Receptor. The effect of PPT 
(50 μM) on the response to NMDA 
(300 μM, with 10 μM glycine) was 
determined in oocytes expressing 
NR1b/NR2A. (A) Representative traces
showing inhibition by 50 μM PPT. 
(B) Summary of percent inhibition 
induced by PPT at the indicated mem-
brane holding potentials in oocytes 
expressing the NMDA receptor. Each
point represents the mean±SEM. (n= 
6∼8/group).
independent of the membrane holding potential (Fig. 5B). 
At membrane holding potentials of －80, －70, －60, －50, 
－40, －30, and －20 mV, PPT inhibited INMDA by 29.9±5.6%, 
32.9±6.6%, 35.9±6.2%, 37.4±3.2%, 38.0±3.3%, 31.0±5.3%, and 
32.2±4.8%, respectively (n=9∼12, from 3 different frogs), in-
dicating that PPT-induced regulations of NMDA receptor 
channel activity is not achieved through interaction with 
channel pore region (Fig. 5B).
DISCUSSION
  Ginsenosides consist of aglycone and carbohydrates por-
tions. The aglycone is the backbone of the ginsenoside, con-
sisting of a hydrophobic 4-ring steroid-like structure that 
can be non-polar, and carbohydrates on carbons-3, 6, and 
20 of the backbone that are polar (Fig. 1A). In vitro and 
in vivo studies have shown that orally administered ginse-
nosides are metabolized and ultimately become aglycones 
such as PPD and PPT [14,15].
  We investigated the effects of ginsenoside metabolites on 
the rat NMDA receptor heterologously expressed in Xenopus 
oocytes. We found that: (1) co-application of PPT but not 
C K  o r  P P D  a l o n g  w i th  N MD A  r e v e r s i b l y  i n h i b i t e d  INMDA 
in a concentration-dependent manner; (2) PPT-mediated 
INMDA inhibition was independent of the concentration of 
NMDA. In other words, a high concentration of NMDA did 
not attenuate PPT action. Finally, (3) PPT-mediated inhibi-
tion of INMDA was membrane holding potential-independent, 
since the effect of PPT on INMDA was not affected by more 
depolarizing membrane potentials. These results suggested 
that PPT might not interact with the NMDA binding site 
or the channel pore region when exerting its effect on INMDA.
  In previous reports, we showed that ginsenoside metabo-
lites such as CK, PPD, and PPT differentially regulate ion 
channels and receptors. For example, CK but not PPT 
strongly inhibited the voltage-dependent α1G-type Ca
2＋ 
channel [10]. Similarly, we found that CK, but not PPT, 
inhibited a neuronal Na
＋ (Nav1.2) channel [12,13]. Recently, 
we also reported that although PPD itself had no effects 
on human HERG K
＋ channel activity, it inhibited the de-
celerating effects on HERG K
＋ channel currents mediated 
by ginsenoside Rg3 [20]. In contrast, with ligand-gated ion 
channels, we demonstrated that PPT, but not CK, inhibited 
5-HT3A receptor-mediated currents [21], and that both CK 
and PPT inhibited α3β4 nicotinic acetylcholine receptor- 
mediated currents [22]. In the present study, we found that 
PPT inhibited NMDA receptor-mediated ion currents. Al-Protopanaxatriol Inhibits NMDA Receptor-Mediated Ion Currents 117
though the previous and present findings demonstrate that 
ginsenosides and ginsenoside metabolites have regulatory 
effects on voltage-dependent and ligand-gated ion channel 
activities, they have differential effects on the regulation 
of ion channels and receptors.
  Interestingly, the previous reports showed that ginseno-
side Rg3, a protopanaxadiol ginsenoside, inhibited NMDA 
receptor-mediated ion currents in cultured hippocampal 
neurons [8,9]. Rg3 is metabolized to PPD, a backbone ginse-
noside structure without carbohydrates. However, in the 
present study, PPD had no effect on INMDA. Therefore, the 
carbohydrate portion attached to carbon-3 of Rg3 might play 
a key role in Rg3-mediated NMDA receptor regulation (Fig. 
1). In contrast, protopanaxatriol ginsenosides, which have 
carbohydrates at carbon-6 and/or -20, induce minimal in-
hibition of NMDA receptor-mediated ion currents in neu-
rons [8]. However, PPT, a metabolite of protopanaxatriol 
ginsenosides, strongly inhibited INMDA (Fig. 1B). The chemi-
cal structure of PPD and PPT differ slightly; PPT has hy-
droxyl group at carbon-6, but PPD does not (Fig. 1A). 
Therefore, the hydroxyl group on carbon-6 of PPT might 
play a key role in PPT-mediated INMDA inhibition (Fig. 1). 
However, elucidation of the exact mechanisms underlying 
the regulation of NMDA receptor by ginsenoside Rg3 or gin-
senoside metabolites will require further studies of the 
structure-function relationship of PPT and Rg3.
  Overstimulation of NMDA receptors in the nervous sys-
tem is closely related to neurotoxicity, neurodegenerative 
diseases, and ischemia [23-25]. Ginsenosides attenuate these 
excitotoxin-mediated insults both in vitro and in vivo [7]. 
The inhibitory effects of a ginsenoside metabolite, PPT, on 
NMDA receptor channel activity might be one of the main 
contributors to neuroprotection against NMDA receptor-re-
lated neurotoxicity after ginsenoside intake and anti-cancer 
activity [8,9]. However, it has been reported that the ma-
jority of ginsenosides are rapidly metabolized in gastric 
juice, the intestine, and the liver, and most ginsenoside me-
tabolites are excreted in the urine [26,27]. The plasma con-
centration of ginsenoside metabolites produced after oral 
administration of ginseng or ginsenosides might be low, in-
cluding PPT, which exhibits various in vitro neuropharma-
cological actions as shown in the present study. Therefore, 
we need to carefully explain the beneficial effects of ginse-
noside metabolites such as PPT in the nervous system.
  In conclusion, when we examined the effects of ginseno-
side metabolites on the INMDA of the rat NMDA receptor 
expressed in Xenopus oocytes, we found that PPT inhibited 
INMDA in a concentration-dependent, non-competitive, and 
membrane holding potential-independent manner. Our re-
sults indicate that PPT, a metabolite of protopanaxatriol 
ginsenosides, could be a novel agent interacting with the 
NMDA receptor, and that the inhibition of INMDA by PPT 
could provide a molecular basis for the pharmacological ac-
tions of ginsenoside metabolites in the nervous system.
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